Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

December 28, 2023

https://www.globenewswire.com/news-release/2023/12/27/2801324/35409/en/Cytokinetics-Announces-Positive-Results-From-SEQUOIA-HCM-the-Pivotal-Phase-3-Clinical-Trial-of-Aficamten-in-Patients-With-Obstructive-Hypertrophic-Cardiomyopathy.html

Statistically Significant and Clinically Meaningful Increase
in Primary Efficacy Endpoint at 24 Weeks of Treatment;
Improvement Consistent Across All Prespecified Subgroups

Read more at globenewswire.com

Related news for (CYTK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.